NovoSphere™Reformulation Platform for Drug Lifecycle Extension
NovoSphere™ empowers pharmaceutical companies to extend the value of existing large and small molecule drugs by reformulating them into long-acting therapies. Whether for new indications or improved compliance, NovoSphere™ supports 505(b)(2) filings and innovative delivery strategies through customized encapsulation.
Primary Benefits of NovoSphere™
Designed to drive commercial impact with controlled drug delivery.
Sustained delivery of small and large molecules at the target site, including the ability to encapsulate drugs already packaged as nanoparticles to further extend release from days to months.
Supports IP expansion via slow-release formulations and new routes of delivery, enabling differentiated versions of existing biologics.
Adds product value without full redevelopment or API modification, accelerating development timelines and lowering cost of goods.
Compatible with a wide range of biologics, including peptides, monoclonal antibodies, vaccines, and extracellular vesicles.
Formulations can be tuned for release profiles spanning hours to months, matching therapeutic need and patient adherence goals.
Enables co-encapsulation of different small and large molecules within a single formulation for synergistic therapeutic effects.
Real-World Applications
NovoSphere™ helps drug developers turn existing therapies into long-acting formulations—improving outcomes and extending commercial viability through modern delivery.
Cancer, Immune Therapy, Cardiovascular Disease
Converted mAbs/peptides requiring daily injections into extended release therapy, reducing treatment burden and enhancing patient adherence.
Product Repositioning
Tailored delivery for new therapeutic targets or unmet clinical needs.
505(b)(2) Applications
Enables regulatory pathways that extend market exclusivity and boost ROI.
“NovoSphere™ completely changed the way we think about antibody delivery. Moving from weekly injections to a once-monthly dose not only improves patient experience but also unlocks tremendous commercial value. The added stability and shelf-life give us access to markets we couldn’t previously reach due to cold chain constraints.”
Explore Other Molecule Delivery Platforms
From injectable gels to protective hydrogels, explore solutions designed for tailored, sustained release of large and small molecules.
Let’s Collaborate
Looking to extend the lifecycle of your drug portfolio? Let’s discuss how NovoSphere™ can help you reformulate and relaunch with confidence.